Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03993314 · ClinicalTrials.gov registry record · Phase 2

Optimizing Anesthesia for Post Partum Tubal Ligations

A Phase 2 study, sponsored by University of Alabama at Birmingham.

Terminated
Registry status
Phase 2
Development phase
15
Enrollment target

NCT03993314 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03993314, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.

TERMINATED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

In this study, the investigators will compare CLOROTEKAL® (1% spinal chloroprocaine) to low-dose isobaric bupivacaine using the epidural volume extension (EVE) technique in patients undergoing post-partum tubal ligation (PPBTL). This will be a randomized, double-blinded study. Patients scheduled for PPBTL at the Women and Infants Center (WIC) will be eligible for enrollment in this study. Outcomes measured will include: ability to achieve an adequate level required for surgery (T6), rate of epidural activation, and duration of the block. The investigators hope to determine the usefulness of each drug using the EVE technique in the setting of PPBTL.

Interventions

  • DRUG Bupivacaine
  • DRUG Chloroprocaine

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2019-08-13
Est. Completion 2020-12-03
Phase Phase 2

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT03993314

The ClinicalTrials.gov registry entry for NCT03993314 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Bupivacaine is the first listed.

NCT03993314 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03993314 about?

NCT03993314 is a clinical study titled "Optimizing Anesthesia for Post Partum Tubal Ligations". In this study, the investigators will compare CLOROTEKAL® (1% spinal chloroprocaine) to low-dose isobaric bupivacaine using the epidural volume extension (EVE) technique in patients undergoing post-partum tubal ligation (PPBTL). This will be a randomized, double-blinded study. Patients scheduled for...

What is the current status of trial NCT03993314?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2019-08-13. Estimated completion is 2020-12-03.

What interventions are being tested in trial NCT03993314?

The interventions under investigation include: Bupivacaine (DRUG), Chloroprocaine (DRUG).

Who is sponsoring clinical trial NCT03993314?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.